Literature DB >> 18313706

Towards understanding the pathology of erythema nodosum leprosum.

I P Kahawita1, D N J Lockwood.   

Abstract

Erythema nodosum leprosum (ENL) is an immune-mediated complication of leprosy presenting with inflammatory skin nodules and involvement of multiple organ systems, often running a protracted course. Immune complex production and deposition as well as complement activation have long been regarded as the principal aetiology of ENL. However, new data show that cell-mediated immunity is also important. We have performed a critical analysis of studies on the pathology of ENL. Our main findings are as follows. ENL is characterised by an inflammatory infiltrate of neutrophils with vasculitis and/or panniculitis. There is deposition of immune complexes and complement together with Mycobacterium leprae antigens in the skin. Changes in serum levels of Igs indicate a transient, localised immune response. The major T-cell subtype in ENL is the CD4 cell, in contrast to lepromatous leprosy where CD8 cells predominate. The cytokines TNFalpha and IL-6 are consistently found whilst IL-4 is low or absent in ENL lesions, indicating a T(H)1 type response. Keratinocyte 1a and intercellular adhesion molecule-1 (ICAM-1) have been shown to be present in the epidermis in ENL, which is evidence of a cell-mediated immune response. Co-stimulatory molecules such as B7-1 have also been studied but further work is needed to draw strong conclusions. We also highlight potential areas for future research.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18313706     DOI: 10.1016/j.trstmh.2008.01.004

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  39 in total

Review 1.  A patient with erythema nodosus leprosum and Chagas cardiopathy: challenges in patient management and review of the literature.

Authors:  Maria Ângela B Trindade; Noemia B Carvalho; Elaini C Belfort; Carla Pagliari; Erika Gakiya; Neusa Y Sakai-Valente; Gil Benard; Maria A Shikanai-Yasuda
Journal:  Am J Trop Med Hyg       Date:  2011-06       Impact factor: 2.345

2.  Transcriptional changes that characterize the immune reactions of leprosy.

Authors:  Kathryn M Dupnik; Thomas B Bair; Andressa O Maia; Francianne M Amorim; Marcos R Costa; Tatjana S L Keesen; Joanna G Valverde; Maria do Carmo A P Queiroz; Lúcio L Medeiros; Nelly L de Lucena; Mary E Wilson; Mauricio L Nobre; Warren D Johnson; Selma M B Jeronimo
Journal:  J Infect Dis       Date:  2014-11-14       Impact factor: 5.226

3.  Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections.

Authors:  David M Tobin; Francisco J Roca; Sungwhan F Oh; Ross McFarland; Thad W Vickery; John P Ray; Dennis C Ko; Yuxia Zou; Nguyen D Bang; Tran T H Chau; Jay C Vary; Thomas R Hawn; Sarah J Dunstan; Jeremy J Farrar; Guy E Thwaites; Mary-Claire King; Charles N Serhan; Lalita Ramakrishnan
Journal:  Cell       Date:  2012-02-03       Impact factor: 41.582

4.  Complement activation in leprosy: a retrospective study shows elevated circulating terminal complement complex in reactional leprosy.

Authors:  N Bahia El Idrissi; S Hakobyan; V Ramaglia; A Geluk; B Paul Morgan; P Kumar Das; F Baas
Journal:  Clin Exp Immunol       Date:  2016-03-31       Impact factor: 4.330

5.  Development of Type 2, But Not Type 1, Leprosy Reactions is Associated with a Severe Reduction of Circulating and In situ Regulatory T-Cells.

Authors:  Ana Paula Vieira; Maria Ângela Bianconcini Trindade; Carla Pagliari; João Avancini; Neusa Yurico Sakai-Valente; Alberto José da Silva Duarte; Gil Benard
Journal:  Am J Trop Med Hyg       Date:  2016-02-22       Impact factor: 2.345

Review 6.  Mycobacterium leprae-host-cell interactions and genetic determinants in leprosy: an overview.

Authors:  Roberta Olmo Pinheiro; Jorgenilce de Souza Salles; Euzenir Nunes Sarno; Elizabeth Pereira Sampaio
Journal:  Future Microbiol       Date:  2011-02       Impact factor: 3.165

Review 7.  Leprosy in the 21st century.

Authors:  Cassandra White; Carlos Franco-Paredes
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

Review 8.  Leprosy in Children.

Authors:  Josafá Gonçalves Barreto; Marco Andrey Cipriani Frade; Fred Bernardes Filho; Moises Batista da Silva; John Stewart Spencer; Claudio Guedes Salgado
Journal:  Curr Infect Dis Rep       Date:  2017-06       Impact factor: 3.725

9.  Lenalidomide alone or lenalidomide plus dexamethasone significantly inhibit IgG and IgM in vitro... A possible explanation for their mechanism of action in treating multiple myeloma.

Authors:  E Shannon; F Sandoval; N Greig; P Stagg
Journal:  Int Immunopharmacol       Date:  2012-01-11       Impact factor: 4.932

10.  Two patients with leprosy and the sudden appearance of inflammation in the skin and new sensory loss.

Authors:  Carlos Franco-Paredes; Jesse T Jacob; Barbara Stryjewska; Leo Yoder
Journal:  PLoS Negl Trop Dis       Date:  2009-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.